Methods for treatment of polycystic kidney disease
AssigneesRegulus Therapeutics Inc., Board of Regents, The University of Texas System
InventorsJohn R. Androsavich, B. Nelson Chau, Vishal D. Patel
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for the treatment of poly-cystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
Claims45
A method of treating polycystic kidney disease comprising administering to a subject in need thereof a compound comprising a modified oligonucleotide consisting of 8 to 25 linked nucleosides, wherein the modified oligonucleotide comprises at least one modified nucleoside, and wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-17 and comprises the nucleobase sequence 5′-GCACTTTG-3′ (SEQ ID NO:
- 3), wherein each T in the nucleobase sequence is independently selected from a T and a U.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.